US Patent 8003780 AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
Patent 8003780 was granted and assigned to Neomics Co., Ltd. on August, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+292 characters)
Article
Patent abstract
The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer.
Edits on 27 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08003780 AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2 US Patent 8003780 AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
Infobox
Patent Number
0800378000
Patent Number
800378000
Edits on 24 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080037800
Date of Patent
August 23, 2011
0Patent Application Number
122559430
Date Filed
October 22, 2008
0Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080037800
Date of Patent
August 23, 2011
0Patent Application Number
122559430
Date Filed
October 22, 2008
0Patent Primary Examiner
Edits on 8 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08003780 AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08003780
Date of patent
August 23, 2011
Patent application number
12255943
Date Filed
October 22, 2008
Patent primary examiner
Find more entities like US Patent 8003780 AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.